logo-loader

ANGLE hails results from landmark ovarian cancer study which underlines potential of its liquid biopsy

Last updated: 12:29 04 Jul 2017 BST, First published: 07:29 04 Jul 2017 BST

ANGLE hails results from landmark ovarian cancer study which underlines potential of its liquid biop
The technology could ultimately help dictate treatment options, streamlining the process

AIM-listed med-tech firm ANGLE plc (LON:AGL,OTCQX:ANPCY) said its ground-breaking liquid biopsy outperformed the current tests used to tell whether a pelvic mass is malignant or benign.

Its Parsortix system was able to detect cancer in 95% of the cases, achieving a lower false positive rate than existing method of detection.

WATCH: ANGLE boss delighted by study results

READ: Our Big Picture overview of the company

ANGLE’s technology was used in harness with a specially-developed algorithm using certain patient data.

Results came from a study of 400 people at two centres – Vienna and New York State.

ANGLE believes the Parsortix blood test has the potential to aid the diagnosis of ovarian cancer before a biopsy or surgery is performed.

Diagnosis before biopsy

Why does this matter? Well, it will allow those with disease to be referred directly to gynaecologic oncology surgeons.

At the same time, it should ensure patients with benign tumours are be cared for in their communities. 

This streamlined strategy has the potential to cut costs and accelerate treatment.

ANGLE’s founder and chief executive said of the latest results: “This success enables ANGLE to move forward into the validation phase for the use of Parsortix in its first clinical application. 

“We believe ANGLE is building momentum towards securing a leading and well differentiated commercial position in the emerging multi-billion dollar liquid biopsy market."

---adds CEO interview---

 

ANGLE PLC present at the Proactive One2One Investor Conference - January 11th

In a comprehensive presentation at the Proactive One2One Investor Conference, ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO, Andrew Newland, and CFO, Ian Griffiths, detailed the company's innovative approach to cancer diagnosis and treatment. Newland emphasised ANGLE's breakthrough technology, the...

on 17/1/24